drug
Spiriva
Marketedupdated 6mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
COPD
all catalysts(0)
nothing on the calendar yet
Trials studying Spiriva
- phase3Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
- phase1A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
- phase4ANTES B+ Clinical Trial
- —Characteristics of Pts Initiating Spiriva Respimat in Asthma
- —Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
- phase4Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD
- phase1A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
- —Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 10, 2027
144 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Apr 16, 2031patentUS 8733341*PED4.4y
- Sep 13, 2028patentUS 7837235*PED1.8y
- Sep 30, 2027patentUS 9027967*PED317d
- Apr 10, 2027patentUS 7396341*PED144d
- Jul 19, 2026patentUS 8022082*PED
- Jan 19, 2026formulationUS 8022082
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that